Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors

Bibliography

• Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87(1):89-99
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-74
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-89
   PubMed Web of Science ®Google Scholar
• Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999;107(1):69-79
   PubMed Web of Science ®Google Scholar
• Stapnes C, Gjertsen BT, Reikvam H, Bruserud O. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opin Investig Drugs 2009;18(4):433-55
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363(22):2091-101
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol 2011;152(5):524-42
   PubMed Web of Science ®Google Scholar
• Reikvam H, Ersvaer E, Bruserud O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets 2009;9(6):761-76
   PubMed Web of Science ®Google Scholar
• Reikvam H, Hatfield KJ, Ersvaer E, et al. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. Br J Haematol 2012;156(4):468-80
   PubMed Web of Science ®Google Scholar
• Lancet JE, Gojo I, Burton M, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010;24(4):699-705
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Karp JE, Litzow MR, et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica 2011;96;11:1619-26
   Google Scholar
• Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008;14(3):250-62
   PubMed Web of Science ®Google Scholar
• Massey AJ, Williamson DS, Browne H, et al. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol 2010;66(3):535-45
   PubMed Web of Science ®Google Scholar
• Bruserud O, Hovland R, Wergeland L, et al. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 2003;88(4):416-28
   PubMed Web of Science ®Google Scholar
• Stapnes C, Doskeland AP, Hatfield K, et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007;136(6):814-28
   PubMed Web of Science ®Google Scholar
• Nissen-Druey C, Tichelli A, Meyer-Monard S. Human hematopoietic colonies in health and disease. Acta Haematol 2005;113(1):5-96
   PubMed Web of Science ®Google Scholar
• Ryningen A, Ersvaer E, Oyan AM, et al. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:bax ratio and low levels of heat shock protein 70 and 90. Leuk Res 2006;30(12):1531-40
   PubMed Web of Science ®Google Scholar
• Bruserud O, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007;92(3):332-41
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Egorin MJ, Eiseman JL, et al. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 2007;13(6):1769-74
   PubMed Web of Science ®Google Scholar
• Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25(34):5410-17
   PubMed Web of Science ®Google Scholar
• Chant ID, Rose PE, Morris AG. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br J Haematol 1995;90(1):163-8
   PubMed Web of Science ®Google Scholar
• Thomas X, Campos L, Mounier C, et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 2005;29(9):1049-58
   PubMed Web of Science ®Google Scholar
• Flandrin P, Guyotat D, Duval A, et al. Significance of heat-shock protein (HSP:) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 2008;13(3):357-64
   PubMed Web of Science ®Google Scholar
• Steiner K, Graf M, Hecht K, et al. High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis. Leukemia 2006;20(11):2076-9
   PubMed Web of Science ®Google Scholar
• Yeh CH, Tseng R, Hannah A, et al. Clinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res 2010;34(5):605-9
   PubMed Web of Science ®Google Scholar
• Powers MV, Clarke PA, Workman P. Death by chaperone: HSP90, HSP70 or both? Cell Cycle 2009;8(4):518-26
   PubMed Web of Science ®Google Scholar
• Powers MV, Jones K, Barillari C, et al. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 2010;9(8):1542-50
   PubMed Web of Science ®Google Scholar
• Williamson DS, Borgognoni J, Clay A, et al. Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design. J Med Chem 2009;52(6):1510-13
   PubMed Web of Science ®Google Scholar
• Bruserud O, Gjertsen BT, Foss B, Huang TS. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of AML cells – the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 2001;19(1):1-11
   PubMed Web of Science ®Google Scholar
• Gjertsen BT, Oyan AM, Marzolf B, et al. Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses. J Hematother Stem Cell Res 2002;11(3):469-81
   PubMedGoogle Scholar
• Reuss-Borst MA, Klein G, Waller HD, Muller CA. Differential expression of adhesion molecules in acute leukemia. Leukemia 1995;9(5):869-74
   PubMed Web of Science ®Google Scholar
• Sioud M, Floisand Y. TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. Eur J Immunol 2007;37(10):2834-46
   PubMed Web of Science ®Google Scholar
• Al Shaer L, Walsby E, Gilkes A, et al. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Br J Haematol 2008;141(4):483-93
   PubMed Web of Science ®Google Scholar
• Bruserud O, Ryningen A, Wergeland L, et al. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 2004;89(4):391-402
   PubMed Web of Science ®Google Scholar
• Elshal MF, McCoy JP. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 2006;38(4):317-23
   PubMed Web of Science ®Google Scholar
• Fredly H, Ersvaer E, Gjertsen BT, Bruserud O. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 2011;25(6):1549-56
   PubMed Web of Science ®Google Scholar
• Bharadwaj S, Ali A, Ovsenek N. Multiple components of the HSP90 chaperone complex function in regulation of heat shock factor 1 In vivo. Mol Cell Biol 1999;19(12):8033-41
   PubMed Web of Science ®Google Scholar
• Hatfield K, Oyan AM, Ersvaer E, et al. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Haematol 2009;144(1):53-68
   PubMed Web of Science ®Google Scholar
• Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud O. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 2005;5(4):229-48
   PubMed Web of Science ®Google Scholar
• Reikvam H, Hatfield KJ, Fredly H, et al. The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. Eur Cytokine Netw 2012;23(4):140-53
   PubMed Web of Science ®Google Scholar
• Reikvam H, Fredly H, Kittang AO, Bruserud O. The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine; the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. Toxins 2013;5(2):336-62
   PubMed Web of Science ®Google Scholar
• Kittang AO, Hatfield K, Sand K, et al. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol 2010;341:149-72
   PubMed Web of Science ®Google Scholar
• Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004;6(6):507-14
   PubMed Web of Science ®Google Scholar
• Mandawat A, Fiskus W, Buckley KM, et al. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood 2010;116(24):5306-15
   PubMed Web of Science ®Google Scholar
• Okawa Y, Hideshima T, Steed P, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009;113(4):846-55
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Andrulis M, Stuhmer T, et al. The PI3K/Akt signalling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2012; Epub ahead of print
   Google Scholar
• Saykally JN, Rachmany L, Hatic H, et al. The nuclear factor erythroid 2-like 2 activator, tert-butylhydroquinone, improves cognitive performance in mice after mild traumatic brain injury. Neuroscience 2012;223:305-14
   PubMed Web of Science ®Google Scholar